Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma

A SEER analysis

Warren H. Tseng, Steve R. Martinez, Ly Do, Robert M. Tamurian, Dariusz Borys, Robert J Canter

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: The benefit of radiation therapy (RT) among patients with retroperitoneal sarcoma (RPS) is controversial. We performed a retrospective analysis of the effect of RT on survival among RPS patients using a nationwide cancer registry. Methods: Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we identified 2308 cases of RPS from 1988 to 2004. We excluded 773 cases for age < 18, identification by autopsy only, absence of histologic confirmation, presence of metastatic disease, or lack of surgical intervention. Overall survival (OS) and disease-specific survival (DSS) were estimated using the Kaplan-Meier method. Multivariate analysis was performed using a Cox proportional hazards model, adjusting for significant covariables. Results: Among 1535 patients who met entry criteria, RT was administered to 373 patients (24.3%). The majority of RT (n = 300, 80.4%) was administered postoperatively. Median OS was 60 and 60 mo, respectively, for patients receiving and not receiving RT (P = 0.59). Median DSS was 86 and 117 mo, respectively, for patients receiving and not receiving RT (P = 0.84). On multivariate analysis, younger age, female gender, low and intermediate histologic grade, liposarcoma histology, tumor size 5-10 cm, and completeness of resection all independently predicted better OS and DSS, while RT did not (HR for OS with RT 0.92, 95% CI 0.78-1.09 and HR for DSS with RT 0.96, 95% CI 0.78-1.17). On subgroup analysis by histology, patients with malignant fibrous histiocytoma (MFH) receiving RT demonstrated statistically improved OS (P = 0.002) and DSS (P = 0.01), respectively. Conclusions: With the possible exception of MFH, postoperative RT offers no survival benefit in RPS. Further studies are necessary to determine if the selective application of RT is indicated.

Original languageEnglish (US)
JournalJournal of Surgical Research
Volume168
Issue number2
DOIs
StatePublished - Jun 15 2011

Fingerprint

Sarcoma
Epidemiology
Radiotherapy
Radiation
Survival
Malignant Fibrous Histiocytoma
Histology
Multivariate Analysis
Liposarcoma
Proportional Hazards Models
Registries
Autopsy
Neoplasms
Databases

Keywords

  • radiation therapy
  • retroperitoneal sarcoma
  • survival

ASJC Scopus subject areas

  • Surgery

Cite this

Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma : A SEER analysis. / Tseng, Warren H.; Martinez, Steve R.; Do, Ly; Tamurian, Robert M.; Borys, Dariusz; Canter, Robert J.

In: Journal of Surgical Research, Vol. 168, No. 2, 15.06.2011.

Research output: Contribution to journalArticle

Tseng, Warren H. ; Martinez, Steve R. ; Do, Ly ; Tamurian, Robert M. ; Borys, Dariusz ; Canter, Robert J. / Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma : A SEER analysis. In: Journal of Surgical Research. 2011 ; Vol. 168, No. 2.
@article{ef12b018ec7f49d38c141392c0e5ee9f,
title = "Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: A SEER analysis",
abstract = "Background: The benefit of radiation therapy (RT) among patients with retroperitoneal sarcoma (RPS) is controversial. We performed a retrospective analysis of the effect of RT on survival among RPS patients using a nationwide cancer registry. Methods: Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we identified 2308 cases of RPS from 1988 to 2004. We excluded 773 cases for age < 18, identification by autopsy only, absence of histologic confirmation, presence of metastatic disease, or lack of surgical intervention. Overall survival (OS) and disease-specific survival (DSS) were estimated using the Kaplan-Meier method. Multivariate analysis was performed using a Cox proportional hazards model, adjusting for significant covariables. Results: Among 1535 patients who met entry criteria, RT was administered to 373 patients (24.3{\%}). The majority of RT (n = 300, 80.4{\%}) was administered postoperatively. Median OS was 60 and 60 mo, respectively, for patients receiving and not receiving RT (P = 0.59). Median DSS was 86 and 117 mo, respectively, for patients receiving and not receiving RT (P = 0.84). On multivariate analysis, younger age, female gender, low and intermediate histologic grade, liposarcoma histology, tumor size 5-10 cm, and completeness of resection all independently predicted better OS and DSS, while RT did not (HR for OS with RT 0.92, 95{\%} CI 0.78-1.09 and HR for DSS with RT 0.96, 95{\%} CI 0.78-1.17). On subgroup analysis by histology, patients with malignant fibrous histiocytoma (MFH) receiving RT demonstrated statistically improved OS (P = 0.002) and DSS (P = 0.01), respectively. Conclusions: With the possible exception of MFH, postoperative RT offers no survival benefit in RPS. Further studies are necessary to determine if the selective application of RT is indicated.",
keywords = "radiation therapy, retroperitoneal sarcoma, survival",
author = "Tseng, {Warren H.} and Martinez, {Steve R.} and Ly Do and Tamurian, {Robert M.} and Dariusz Borys and Canter, {Robert J}",
year = "2011",
month = "6",
day = "15",
doi = "10.1016/j.jss.2011.02.004",
language = "English (US)",
volume = "168",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma

T2 - A SEER analysis

AU - Tseng, Warren H.

AU - Martinez, Steve R.

AU - Do, Ly

AU - Tamurian, Robert M.

AU - Borys, Dariusz

AU - Canter, Robert J

PY - 2011/6/15

Y1 - 2011/6/15

N2 - Background: The benefit of radiation therapy (RT) among patients with retroperitoneal sarcoma (RPS) is controversial. We performed a retrospective analysis of the effect of RT on survival among RPS patients using a nationwide cancer registry. Methods: Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we identified 2308 cases of RPS from 1988 to 2004. We excluded 773 cases for age < 18, identification by autopsy only, absence of histologic confirmation, presence of metastatic disease, or lack of surgical intervention. Overall survival (OS) and disease-specific survival (DSS) were estimated using the Kaplan-Meier method. Multivariate analysis was performed using a Cox proportional hazards model, adjusting for significant covariables. Results: Among 1535 patients who met entry criteria, RT was administered to 373 patients (24.3%). The majority of RT (n = 300, 80.4%) was administered postoperatively. Median OS was 60 and 60 mo, respectively, for patients receiving and not receiving RT (P = 0.59). Median DSS was 86 and 117 mo, respectively, for patients receiving and not receiving RT (P = 0.84). On multivariate analysis, younger age, female gender, low and intermediate histologic grade, liposarcoma histology, tumor size 5-10 cm, and completeness of resection all independently predicted better OS and DSS, while RT did not (HR for OS with RT 0.92, 95% CI 0.78-1.09 and HR for DSS with RT 0.96, 95% CI 0.78-1.17). On subgroup analysis by histology, patients with malignant fibrous histiocytoma (MFH) receiving RT demonstrated statistically improved OS (P = 0.002) and DSS (P = 0.01), respectively. Conclusions: With the possible exception of MFH, postoperative RT offers no survival benefit in RPS. Further studies are necessary to determine if the selective application of RT is indicated.

AB - Background: The benefit of radiation therapy (RT) among patients with retroperitoneal sarcoma (RPS) is controversial. We performed a retrospective analysis of the effect of RT on survival among RPS patients using a nationwide cancer registry. Methods: Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we identified 2308 cases of RPS from 1988 to 2004. We excluded 773 cases for age < 18, identification by autopsy only, absence of histologic confirmation, presence of metastatic disease, or lack of surgical intervention. Overall survival (OS) and disease-specific survival (DSS) were estimated using the Kaplan-Meier method. Multivariate analysis was performed using a Cox proportional hazards model, adjusting for significant covariables. Results: Among 1535 patients who met entry criteria, RT was administered to 373 patients (24.3%). The majority of RT (n = 300, 80.4%) was administered postoperatively. Median OS was 60 and 60 mo, respectively, for patients receiving and not receiving RT (P = 0.59). Median DSS was 86 and 117 mo, respectively, for patients receiving and not receiving RT (P = 0.84). On multivariate analysis, younger age, female gender, low and intermediate histologic grade, liposarcoma histology, tumor size 5-10 cm, and completeness of resection all independently predicted better OS and DSS, while RT did not (HR for OS with RT 0.92, 95% CI 0.78-1.09 and HR for DSS with RT 0.96, 95% CI 0.78-1.17). On subgroup analysis by histology, patients with malignant fibrous histiocytoma (MFH) receiving RT demonstrated statistically improved OS (P = 0.002) and DSS (P = 0.01), respectively. Conclusions: With the possible exception of MFH, postoperative RT offers no survival benefit in RPS. Further studies are necessary to determine if the selective application of RT is indicated.

KW - radiation therapy

KW - retroperitoneal sarcoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=79955790441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955790441&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2011.02.004

DO - 10.1016/j.jss.2011.02.004

M3 - Article

VL - 168

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -